NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders with a market capitalization of $439 million, has been making significant strides in the epilepsy ...

Responsive neurostimulation has also shown promising results, particularly in patients with idiopathic generalized epilepsy (IGE). A case series reported significant reductions in seizure ...

Patients' ages ranged from 0.5 to 197.4 months. The cause of generalized convulsive status epilepticus was idiopathic or febrile convulsions in two thirds of cases. Most (89%) patients were ...

These children show myoclonic jerks and/or epilepsy with generalized tonic-clonic seizures only in response to a visual stimulus. Visually induced and spontaneous seizures, with or without a ...

The study is scheduled to commence early this year and will be followed by a subsequent proof of concept efficacy study in dogs with epilepsy. The potential new idiopathic epilepsy therapy has ...